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Abstract
Background: Alterations in the stem cell niche are likely to contribute to tumorigenesis; however, the concept of niche
promoted benign tumor growth remains to be explored. Here we use keloid, an exuberant fibroproliferative dermal growth
unique to human skin, as a model to characterize benign tumor-like stem cells and delineate the role of their ‘‘pathological’’
niche in the development of the benign tumor.
Methods and Findings: Subclonal assay, flow cytometric and multipotent differentiation analyses demonstrate that keloid
contains a new population of stem cells, named keloid derived precursor cells (KPCs), which exhibit clonogenicity, self-
renewal, distinct embryonic and mesenchymal stem cell surface markers, and multipotent differentiation. KPCs display
elevated telomerase activity and an inherently upregulated proliferation capability as compared to their peripheral normal
skin counterparts. A robust elevation of IL-6 and IL-17 expression in keloid is confirmed by cytokine array, western blot and
ELISA analyses. The altered biological functions are tightly regulated by the inflammatory niche mediated by an autocrine/
paracrine cytokine IL-17/IL-6 axis. Utilizing KPCs transplanted subcutaneously in immunocompromised mice we generate
for the first time a human keloid-like tumor model that is driven by the in vivo inflammatory niche and allows testing of the
anti-tumor therapeutic effect of antibodies targeting distinct niche components, specifically IL-6 and IL-17.
Conclusions/Significance: These findings support our hypothesis that the altered niche in keloids, predominantly
inflammatory, contributes to the acquirement of a benign tumor-like stem cell phenotype of KPCs characterized by the
uncontrolled self-renewal and increased proliferation, supporting the rationale for in vivo modification of the ‘‘pathological’’
stem cell niche as a novel therapy for keloid and other mesenchymal benign tumors.
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Introduction
Keloid is an exuberant scar unique to human with highest
incidence in African-Americans, resembles benign tumor behavior
by its aggressive dermal growth that continues to expand beyond
the boundaries of the original wound margins (Figure S1A), rarely
regresses as observed in hypertrophic scars [1], and recurs at a
high rate after surgical removal [2]. A more tolerable and effective
modality for keloid treatment is intralesional steroid injection,
however, not applicable to very large or multiple keloids [3].
These dermal growths, similar to other fibroid tumors, could
potentially reach a grotesque size in the craniofacial region with
tremendous esthetic, functional, and psychologically debilitating
sequelae [1]. As a chronic inflammatory and fibro-proliferative
disease (Figure S1A), keloids exhibit distinctive histological features
including a high density of mesenchymal cells, an abundant ECM
stroma characterized of whorls of irregularly oriented and
thickened hyalinized collagen bundles that are classically described
as keloidal collagen [4], a local infiltration of inflammatory cells
including mast cells and lymphocytes, and a milieu of enriched
cytokines, especially transforming growth factor-b1 (TGF-b1) and
IL-6 [5,6]. Clinically, keloids have been correlated with some
degree of inflammatory response associated with tissue injury and
most often, manifested clinically as a tender, painful, pruritic or
burning sensation. We postulate that the altered or ‘‘pathological
niche’’ driven by the inflammatory cytokine IL-17/IL-6 axis
potentially regulates the benign, yet aggressive growth behavior of
the dermal tumor. A recent study suggests that the interaction
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to keloid formation by triggering progressive myofibroblastic
differentiation and secretion of abundant extracellular matrix [7].
In addition, the fibroproliferative nature of keloids suggests that
mesenchymal stem cells may serve as primary source of
multipotent cells to rapidly repopulate the wound site in response
to exogeneous insults, such as trauma, surgical injury, or infection.
Therefore, keloids provide an ideal benign tumor model to study
the role of stem cells and their special niche components in
promoting and maintaining the proliferative growth of the dermal
scar.
The fate of the stem cells, undergoing self-renewal or
differentiation, is dependent on a specialized microenvironment
or niche in which the cells reside [8]. The stem cell niche [9]
encompasses all elements immediately surrounding the stem cells,
including non-stem cells, the extracellular matrix (ECM), as well as
soluble molecules present in the locale [10,11]. Under homeostatic
or physiological conditions, the extrinsic niche components or
growth factors protect the stem cells from excessive proliferation
by providing a balanced proliferation-inhibiting and proliferation-
promoting signal [12,13]. Meanwhile, the stem cells must
periodically activate to produce specific lineage progenies for the
regeneration or repair of tissues [10]. Therefore, the maintenance
of a steady state between stem cell quiescence and activity is the
hallmark of a functionally normal niche [13], whereas the
deregulation of niche signals may lead to the uncontrolled self-
renewal and proliferation of the stem cells, thus contributing to the
emergence of the so-called niche-generated diseases including pre-
cancer and tumorigenesis [11,14].
Interleukin (IL)-6 is produced at the site of acute inflammation
[15] and plays a critical role in both cellular and humoral immune
responses [16]. IL-6 can trigger the switch from acute to chronic
inflammation by enhancing the recruitment of monocytes [17],
thereby, serving as a key player in both acute and chronic
inflammation [18]. Numerous studies have reported elevated IL-6
levels in several inflammatory diseases, including chronic inflam-
matory and fibro-proliferative diseases such as keloids [5,6],
rheumatoid arthritis, inflammatory bowel disease (colitis), multiple
sclerosis, and pulmonary fibrosis [19,20]. Aside from its established
function as an immuno-modulator, IL-6 may contribute to the
regulation of stem cell functions via several pathways leading to
the inhibition of lymphocyte apoptosis [21] and the maintenance
of hematopoietic stem cells [22]. Most recently, IL-6 has been
reported as a critical tumor promoter during early colitis-
associated tumorigenesis [23,24]. Immune cells, which often
infiltrate tumor and pre-neoplastic lesions, are capable of
perpetuating a localized inflammatory response via a variety of
cytokines and chemokines, and enhancing the growth and survival
of premalignant cells. IL-6 has also been demonstrated to trigger
malignant features in Notch-3-expressing stem/progenitor cells
from human ductal breast carcinoma and normal mammary gland
[25] and further up-regulates telomerase activity in human
malignancies [26,27]. Since telomerase plays an essential role in
the regulation of cell proliferation and senescence [28,29] it has
been routinely used as a functional marker to assess stem cell
function and tissue homeostasis [30,31].
IL-17, a recently discovered pro-inflammatory cytokine, is
secreted by a distinct subtype of activated CD4
+ T-cells known as
Th17 [32,33]. Most recently, several studies have clearly
demonstrated the critical role of TGF-b and IL-6 or other
inflammatory cytokines in the differentiation of human Th17 cells
[34–37]. The finding of this cytokine has changed our perspectives
on chronic inflammatory diseases, including inflammatory bowel
disease, rheumatoid arthritis, psoriasis, multiple sclerosis, and
allergic skin immune responses [38–41]. IL-17 is produced
exclusively by activated T cells, however, its receptor is
ubiquitously expressed in many cell types, thus making them
potential targets [35,42]. IL-17 amplifies the immune response
mediated by a variety of cytokines such as IL-6, tumor necrosis
factor (TNF)- a and IL-1b, chemokines such as monocyte
chemoattachment protein-1 (MCP-1) and macrophage inflamma-
tory protein-2 (MIP-2)/IL-8, cell-surface markers such as inter-
cellular adhesion molecule-1 (ICAM-1), and pro-inflammatory
mediators including prostaglandin E2, nitric oxide, cyclooxygen-
ase-2, and C-reactive protein [43–47]. Among these inflammatory
cytokines, IL-6 seems to be a major IL-17 signaling target in a
variety of cells including macrophages, fibroblasts, osteoblasts,
epithelial cells, and chondrocytes [44,45,48–51]. More important-
ly, IL-6 not only functions downstream of IL-17 but also acts as a
critical upstream target of IL-17, thus forming a paracrine/
autocrine feedback loop that promotes autoimmune and allergic
diseases [50,51]. In addition to its immuno-regulatory role, IL-17A
promotes the proliferation, migration, and osteogenic differentia-
tion of human bone marrow mesenchymal stem cells (BMMSCs)
[52]. Based on existing findings we asked whether IL-17 and IL-6
coordinately interact and contribute to the persistent local tissue
inflammation in keloid, i.e. sustaining the ‘‘pathological’’ niche,
therefore support the proliferation-promoting signal of the benign
dermal growth.
Previously, stem cells derived from the dermis have been
isolated and cultured under either adherent conditions with fetal
bovine serum (FBS)-containing medium [53] or neural sphere-
forming condition in serum free medium supplemented with
epidermal growth factor (EGF) and fibroblast growth factor (FGF)-
2 [54,55,56]. In the current study, using both adherent and
sphere-culturing conditions we have isolated and characterized a
population of adult stem cells from the dermal layer of keloid scars,
named keloid derived precursor cells (KPCs), which are charac-
terized by several defined stem cell features including clonogeni-
city, self-renewal, expression of distinct embryonic and mesenchy-
mal stem cell markers, and multipotent differentiation. We have
also defined an essential inflammatory cytokine paracrine loop
between IL-17 and IL-6, constituting the ‘‘pathological’’ keloid
niche that is capable of elevating the proliferation-promoting
signal. Using KPCs transplanted in immunocompromised mice we
generate a keloid-like tumor model that is driven by the in vivo
inflammatory niche. Understanding how the inflammatory niche
regulates tumor-like stem cell growth in keloid is critical in further
elucidation of keloid pathogenesis and will open a new avenue for
benign tumor stem cell research and ultimately, keloid therapies.
Materials and Methods
Ethics Statement
This study followed the tenets of the Declaration of Helsinki and
all keloid tissues were obtained as discarded biological samples
from patient donors (aged 20,50 years of age) after a written
informed consent was provided. This study was approved by the
Institutional Ethics Committee/Institutional Review Board (IRB)
of both University of Southern California and Harbor-UCLA/
King Drew Medical Center.
Antibodies and reagents
All antibodies used in this study were listed in Table S1.
Recombinant human interleukin-6 and interleukin-17A were
purchased from PeproTech Inc. (Rocky Hills, NJ, USA). All
chemical reagents were analytical grade and obtained from
Sigma-Aldrich (St. Louis, MO).
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C57BL/6 mice were purchased from Jackson Lab. Immuno-
compromised mice (bg-nu/nu-xid) were purchased from Harlan
Sprague Dawley Inc. (Indianapolis, IN) and were used for in vivo
transplantation experiments under the approved animal protocol
of University of Southern California (USC #10874).
Cell isolation and culture
Keloid and matched peripheral normal skin tissues were
obtained from the same patient donor and were used for isolation
of stem cells. At least 5 sets of keloid derived progenitor cells
(KPCs) with appropriately matched skin derived progenitor cells
(SKPs) were derived from 5 unrelated patients [(3 African-
Americans (2 females, 1 male), 2 Hispanics (1 female, 1 male)], and
were used in all experiments described. SKPs were also derived
from normal skin tissues from other donors. Tissues were treated
aseptically, cut into 5–6 mm pieces, and incubated in sterile
phosphate-buffered saline solution (PBS) containing 3 mg/mL
dispase (Sigma) overnight at 4uC. The epidermis was manually
stripped off; the dermal portion was minced into 1-mm
3 pieces,
digested in sterile PBS containing 4 mg/mL collagenase I
(Worthington Biochemical Corporation, Lakewood, NJ) for
2 hours at 37uC [54,57], filtered through a 70 mm cell strainer
(Falcon, Franklin Lakes, NJ), and the isolated cells were cultured
under two different conditions. For sphere-forming culture
[54,55,56], cells were seeded on uncoated dishes with growth
medium, Dulbecco’s minimum essential medium with low glucose
(DMEM-LG)/F12 (3:1) (Invitrogen, Carlsbad, CA) supplemented
with 40 ng/ml fibroblast growth factor (FGF-2), 20 ng/ml
epidermal growth factor (EGF) (Chemicon, Billerica, MA), B27,
1 mg/ml fungizone and 100 U/ml penicillin/100 mg/ml strepto-
mycin (Invitrogen). After 2,4 weeks, spheres were formed and
further sub-cultured in 60 mm ultra-low culture dishes (Corning
Inc., Corning, NY). For cell attachment or MSC culture, cells
were cultured as described previously with some modifications
[53]. Briefly, resuspended cells were plated on non-treated 10-cm
Petri dishes (VWR Scientific Products, Willard, OH) with
minimum essential medium (MEM: Invitrogen) containing 10%
fetal bovine serum (FBS: Clontech Laboratories, Inc., Mountain
View, CA), 100 U/ml penicillin, 100 mg/ml streptomycin (Invi-
trogen), 2 mM L-glutamine, 100 mM non-essential amino acid
(NEAA), and 550 mM 2-mercaptoethanol (2-ME; Sigma-Aldrich),
and cultured at 37uC in a humidified tissue-culture incubator with
5% CO2 and 95% O2. The confluent cells were passaged with
0.05% trypsin containing 1 mM EDTA, and continuously
subcultured in the complete growth medium.
Colony forming unit fibroblasts (CFU-F) assay
The CFU-F assay was performed as previously described
[58,59]. Cell aggregates containing more than 50 cells were
counted as colonies using a dissecting microscope. The CFU-F
assay was repeated in 5 independent experiments.
Single cell cloning
Precursor cells isolated from keloid tissues and matched
peripheral normal skin samples of different donors were seeded
in non-coated tissue culture 96-well plates (Falcon) at a
concentration of 2 cells/ml (200 ml/well, at least 4 plates/donor).
The plates were screened for presence of single cell colony while
wells contained more than two colonies were excluded from
further analysis. Wells containing a single cell were allowed to
reach confluency, transferred to 24-well dishes, and further
expanded in the growth medium [57].
Population doubling assay
Clonal dermal precursor cells at each passage (P2, P5, P10 and
P20) were seeded at 1.0610
3 cells in 35-mm dishes in MSC
medium for each period (0, 2, 4, 6, 8, 10 days). Cells were
suspended with 0.05% trypsin-EDTA and cell number was
determined by hemacytometer. Population doubling time (PDT)
was calculated with the formula, PDT=(t-t0)*lg2/lg(N/N0)( N 0
and N represent the cell numbers at time t0 and t, respectively).
Meanwhile, the accumulated population doublings were deter-
mined and calculated according to the standard 3T3 protocol as
described previously [60].
Multipotent differentiation
We tested the in vitro multi-differentiation capabilities of dermal
precursor cells including osteogenesis, adipogenesis and neural cell
differentiation as described in Methods S1.
Stimulation of cells with IL-6 or IL-17
KPCs and SKPs at 70,80% confluence were serum-starved
(medium containing 1% FBS) for 24 hours followed by exposure
to different concentrations of IL-6 or IL-17 (R & D Systems).
Under certain conditions, to clarify the role of IL-17/IL6 axis in
the regulation of KPC functions, the serum-starved cells were
pretreated with different concentrations of specific neutralizing
antibodies for human IL-6 or IL-17 or an isotype-matched control
IgG (R & D Systems) for 1 hour followed by stimulation with IL-6
or IL-17 for 24 hours. Then whole cell lysates or total RNA were
extracted and subjected to Western blot and RT-PCR analysis,
respectively.
Cell proliferation assay
The proliferation of dermal precursor cells was assessed by
5-bromo-2-deoxyuridine (BrdU) incorporation using a BrdU
staining kit (Invitrogen) as previously described [55]. To quantify
cell proliferation capacity, ten representative images were used to
enumerate BrdU-positive cells and quantitated as a percentage of
BrdU-positive cells over total nucleated cells.
Flow cytometric analysis
Approximately 5610
5 cells were incubated with phycoerythrin
(PE)- or fluorescein isothiocyanate (FITC)-conjugated mouse
monoclonal antibodies specific for human CD34, CD45,
CD105, CD146, CD29, CD73, CD90, and Stro-1, or incubated
with purified mouse monoclonal antibodies specific for human IL-
6 receptor (IL-6R) and IL-17 receptor (IL-17R) followed by
incubation with FITC-conjugated secondary antibodies (Table
S1). The labeled cells were subjected to EpicsH XL-MCL
Beckman Coulter flow cytometer, and analyzed using the Expo32
program (USC Clinical Pathology Reference Lab). Cell samples
incubated in the absence of primary antibody or with an isotype-
matched control IgGs (Southern Biotech, Birmingham, AL) were
used as negative controls [58,59].
Reverse transcription–polymerase chain reaction (RT-
PCR) and quantitative real-time PCR (qPCR)
Total RNA was isolated from cultured cells using TRIZOL
H
Reagent (Invitrogen). RT-PCR was carried out using the One-step
RT-PCR Kit (QIAGEN, Valencia, CA), whereby the number of
amplification cycles and the amplifying condition for individual
target genes were determined to be in the linear range. To confirm
RT-PCR results in some experiments, qPCR was performed using
the iScript one-step RT-PCR kit with SYBR Green (BioRad,
Hercules, CA) according to the manufacturer’s instructions. As an
Niche-Driven Overgrowth of KPC
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the target genes. All primers (Table S2) were synthesized at the
Core Facility at Norris Comprehensive Cancer Center, USC.
Western blotting
We performed electrophoresis of protein extracts prepared from
cultured cells or tissue lysates followed by immunoblotting as
previously described [57]. Blots were incubated with primary
antibodies at a dilution of 1:1000,1:2000 followed by horseradish
peroxidase (HRP)-conjugated secondary antibodies (PIERCE,
Rockford, IL), and visualized by the enhanced chemiluminescence
light method (PIERCE). For standardization, blots were re-probed
with mouse antibody to human b-actin.
Cytokine antibody array
To analyze the cytokine expression profile of tissue lysates we
utilized the RayBio Human Cytokine Antibody Array 3
(RayBiotech, Inc., Norcross, GA), which allows the detection of
42 cytokines, chemokines and growth factors in one experiment
following manufacturer’s protocol.
Telomerase activity and telomeric length assay
The telomerase activity was measured using the telomere repeat
amplification protocol (TRAP) TeloTAGGG telomerase PCR
ELISA kit (Roche Diagnostics, Indianapolis, IN). The telomerase-
mediated elongated product was detected by hybridization to
digoxigenin-labeled probes and enzyme activity quantified by
photometric enzyme immunoassay.
Enzyme-linked immunoassay (ELISA)
The level of IL-6 and IL-17 in tissue and cell lysates was
detected using human IL-6 ELISA Ready-SET-Go (eBioscience,
San Diego, CA) and human or mouse IL-17 Quantikine ELISA
Kit (R&D Systems, Minneapolis, MN), respectively, following the
manufacturers’ instructions.
In vivo transplantation
Transplantation studies were carried out using KPCs and
matched SKPs derived from five different donors, and each
transplantation was done in triplicates (n=3). Approximately
2.0610
6 stem cells mixed with 40 mg of hydroxyapatite/
tricalcium phosphate (HA/TCP) ceramic powder (Zimmer Inc.,
Warsaw, IN), or Gelfoam (3 mm63m m 62 mm, Pharmacia,
Piscataway, NJ), were subcutaneously transplanted into the dorsal
surface of 8–10-week-old female immunocompromised mice as
previously described [55,56]. Serial transplantation was described
in Methods S. For the hydrogel carrier transplant, we mixed
2.0610
6 cells with Heprasil
TM (CMHA-S, thiol-modified hya-
luronic acid with thiol-modified heparin) and Gelin-S
TM (GTN-
DTPH, thiol-modified gelatin) (1:1) with or without IL-6, and then
combined with Extralink
TM (PEGDA, polyethylene glycol diacry-
late) (4:1) (Glycosan Biosystems, Salt Lake City, UT). The
immobilized heparin in Heprasil
TM mimics the heparan sulfate
proteoglycans of the extracellular matrix with increased avidity for
growth factors by forming non-covalent binding to the polymer
network, prevents proteolysis, and maintains their bioactive state
with a slow release over several weeks (Glycosan Biosystems)
[61,62]. The mixtures were immediately injected subcutaneously
into the dorsal surface of 8–10-week-old female immunocompro-
mised mice.
To further investigate the role of IL-6 in the initiation of KPC-
generated transplants, KPCs mixed with hydrogel with or without
human IL-6 neutralizing antibody (10 mg/ml) were injected
subcutaneously into immunocompromised mice for 8 weeks. On
the other hand, to investigate the role of IL-6 in the maintenance
of KPC-generated transplants, KPCs mixed with hydrogel were
injected subcutaneously into immunocompromised mice for 4
weeks, followed by intra-lesional injection of IL-6 neutralizing
antibody twice a week (5 mg/time) for another 5 weeks. In all
cases, an isotype-matched normal mice IgG was used as negative
control.
Adaptation of activated CD4
+CD25
2 T-lymphocytes in
immunocompromised mice
Spleens were harvested from C57BL/6 mice for isolation of
CD4
+CD25
2 T-lymphocytes using MidiMACS separator (Milte-
nyi Biotec) and mouse CD4
+CD25
+ T lymphocyte isolation kit
(Miltenyi Biotec) following manufacturer’s instruction. The purity
of the CD4
+CD25
2 T cells was .95%. The cells were seeded at
1610
6/well on 24-well multi-plates and cultured in RPMI-1640
medium containing 10% FBS, 50 mM 2ME, 10 mM HEPES,
1 mM sodium pyruvate, 1% NEAA, 2 mM L-glutamine, 100 U/
ml penicillin and 100 mg/ml streptomycin followed by stimulation
with 5 mg/ml plate-bounded anti-CD3 antibody (BD Biosciences)
and 2 mg/ml soluble anti-CD28 (BD Biosciences). After three
days, activated cells were collected and washed with normal saline
[63]. 1610
6/mouse of the activated CD4
+CD25
2 T lymphocytes
were injected into immunocompromised mice through tail vein
two days before KPCs mixed with hydrogel with or without IL-6
were transplanted subcutaneously. In parallel, transplants in mice
without infusion of T cells were used as controls.
Histology and immunohistochemistry
Keloid and matched peripheral normal skin tissues, normal skin
and normal scar tissues from both African-American and
Caucasian patient donors, and transplant samples were fixed with
10% formalin in PBS or embedded in O.C.T. compound (Sakura,
Tokyo, Japan) and snap frozen in liquid nitrogen. Procedures for
immunohistochemical studies and electron microscopy were
described in Methods S1.
Immunofluorescence studies
4% paraformaldehyde-fixed cultured cells and sections of
normal and keloid tissue samples were immunolabeled with
specific primary antibodies followed by FITC- and/or PE-
conjugated secondary antibodies (BD Biosciences). After the nuclei
were stained with 49, 6-diamidino-2-phenylindole (DAPI) the
samples were observed under a confocal microscope. Isotype-
matched control antibodies (Invitrogen) were used as negative
controls. Positive signals in at least 5 random fields were visualized
and counted.
Statistical analysis
All data are expressed as mean6SEM from at least five
independent experiments. Differences between experimental and
control groups were analyzed by two-tailed unpaired Student’s
t-test using SPSS. P-values less than 0.05 were considered
statistically significant.
Results
Keloid contains benign tumor-like stem cells
Aside from the characteristic histological features of abundant
ECM stroma, specifically large collagen bundles (Figure S1B),
hyper-cellular and inflammatory states, the keloid tissue harbors
an elevated level of Octamer-4 (Oct-4) and stage specific
Niche-Driven Overgrowth of KPC
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in the reticular dermis as compared to matched normal skin of the
same donor (Figure 1A; Figure S1C). The relatively increased
expression of two major markers for embryonic and mesenchymal
stem cells [54,64,65], Oct-4 and SSEA-4, in keloid tissues as
compared to matched normal skin was further confirmed by
Western blot (Figure 1B), suggesting that keloid may harbor more
postnatal stem cells than normal skin.
Next, we isolated a population of adult stem cells from keloid
dermis, named keloid derived precursor cells (KPCs), from 5
independent donors and assess their colony formation and
proliferation. Normal skin-derived precursor cells, termed SKPs
[54], were derived from matched normal skin of the same donor.
Colony formation was observed on day 3 (Figure S1D) in 6,8% of
KPCs whereas only 2,4% in normal skin precursor cells (SKPs)
(Figure 1C), suggesting higher colony-forming capabilities of the
tumor-like stem cells in keloids. Single colony formation was
further confirmed using diluting seeding density at 2 cells/ml
(200 ml per well) (Figure S1E). At early passages (less than passage
5), both KPCs and SKPs exhibited similar doubling time and
cumulative population doublings; however, at a later passage,
KPCs showed a relatively increased growth rate compared to
Figure 1. Identification of dermal derived precursor cells from keloid tissues. A, Frozen sections of keloid tissues and their matched
peripheral normal skins were immunostained with specific antibodies for human Oct-4 and SSEA-4. Scale bars, 50 mm. B, Expression of Oct-4 and
SSEA-4 in keloids (K1, K2) and matched normal skins (N1, N2) were determined by Western blot analysis and scanning densitometer. C, Colony
formation analysis of cells derived from keloids and normal skin (mean6SEM). * P,0.05; ** P,0.01. D, Cell population doubling numbers were
determined in single cell colony-derived stem cells from keloids (KPCs) and matched peripheral normal skins (SKPs) by standard 3T3 cell culture
protocol (mean6SEM). E, Flow cytometric analysis of cell surface markers of KPCs and SKPs. F, RT-PCR (upper panel) and qPCR (lower panel) analysis
of stem cell genes of KPCs (K1, K2) and SKPs (N1, N2). G and H, Analysis of telomerase activity using TeloTAGGG telomerase PCR ELISA kit
(mean6SEM). * P,0.05; ** P,0.01; *** P,0.001. Data are representative of at least five independent experiments using specimens obtained from
different patient donors with matched normal controls (n=5).
doi:10.1371/journal.pone.0007798.g001
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doublings and a reduction in doubling time (Figure 1D; Figure
S1F). G-banding analysis (Methods S1) demonstrated normal
karyotype with no cytogenetic abnormalities in both SKPs and
KPCs (Figure S1G), suggesting the maintenance of chromosomal
stability in these derived stem cells. These results suggest that
keloid-derived stem cells maintain a relatively higher proliferative
rate than their normal skin counterparts, and this inherent rapid
growth appears unrelated to mutational changes observed in
malignant tumor.
Up to date, efforts have been made to develop a cell-surface
antigen profile for better purification and identification of
mesenchymal stem cells (MSCs) from different tissue sources
[10]. There is a consensus that human MSCs rarely express
markers of hematopoietic cells such as CD45 and CD34
[10,64,66]. Several positive markers such as Stro-1, CD73, and
CD106 were considered the most useful and relatively specific
markers for MSCs [10], but others including CD90/Thy-1 were
relatively non-specific, although frequently expressed on MSCs
from different tissues [10,64,66]. To characterize stem cell
phenotypic markers of KPCs using flow cytometry, we observed
that a high percentage of both KPCs and SKPs expressed CD90 at
passage 2–6 (Figure 1E). However, only 11% and 46.4% of KPCs
expressed CD29 and CD73, respectively, as compared to 77.6%
for CD29 and 77.1% for CD73 in SKPs (Figure 1E). Interestingly,
the percentage of KPCs expressing Stro-1 (19.1%) and CD105
(4.5%) was consistently higher than that of SKPs (Figure 1E).
Similar expression profiles of cell surface molecules were observed
in SKPs and KPCs up to 10 passages (data not shown). The
differential expression of mesenchymal stem cell marker profiles
suggests KPCs are uniquely distinct from SKPs.
We next examined several specific stem cell genes expression
using quantitative real-time PCR (qPCR). KPCs expressed
relatively higher levels of Oct-4, Rex-1, Nanog, and human
telomerase reverse transcriptase (hTERT) mRNAs than SKPs
(Figure 1F). In addition, comparative analysis of telomerase
activity using Telo TAGGG telomerase PCR ELISA showed that
KPCs displayed an inherently higher telomerase activity (5–6
folds) as compared to normal skin stem cells (Figure 1G). Unlike
cancer, both KPCs and SKPs showed significantly lower level of
telomerase activities than cancer cells (Figure 1G), and gradually
decreased with increasing cell passages (Figure 1H) suggesting a
tighter growth regulation. Taken together, these results suggest
that KPCs differ from SKPs in terms of distinct surface marker
expression profile, elevated expression of several specific stem cell
genes, and increased capability of colony formation and
proliferation, thus resembling benign tumor-like properties.
Keloid-derived precursor cells are capable of multiple
differentiation
The multi-differentiation potential of KPCs was determin-
e da n dc o m p a r e dt ot h a to fS K P s .U n d e ra d i p o g e n i ca n d
osteogenic induction conditions, both SKPs and KPCs could
differentiate into adipocytes and osteoblasts as determined by
Oil Red O staining (Figure S2A) and by Alizarin Red S staining
(Figure S2D), respectively. Adipogenic differentiation was
further confirmed by the increased expression of specific
adipogenic markers including peroxisome proliferators-activat-
ed receptor c2 (PPARc2), aP2 and lipoprotein lipase (LPL) as
determined by RT-PCR (Figure S2C). Similarly, the osteogenic
induction of KPCs and SKPs was further supported by the
increased expression of osteocalcin, an osteogenic marker
(Figure S2F). In addition, quantification of the Oil Red O and
Alizarin Red S (Figures S2B and S2E) staining using 5 random
fields as well as RT-PCR results (Figures S2C and S2F) showed
a moderate increase in the expression of adipogenic and
osteogenic markers in differentiated KPCs compared to
differentiated SKPs. However, further evidence is needed to
determine whether KPCs have a relatively stronger capability
to differentiate toward adipogenesis and osteogenesis as
compared to SKPs. Meanwhile, we demonstrated that keloid-
derived sphere colonies (Figure S3) were capable of multipotent
differentiation into distinct lineages including mesoderm-
derived adipocytes, osteoblasts and smooth muscle cell-like
cells, and ectoderm-derived different types of neural cells
(Figure S3D). These findings consistent with previous stem cell
properties described in rodent and mammalian skin-derived
precursors or SKPs [54,55,56] indicate that keloid derived stem
cells may represent an active form of SKPs.
KPCs are capable of regenerating connective tissues after
in vivo transplantation
To explore the in vivo regenerative capability, the expanded
KPCs and SKPs (2610
6) were subcutaneously transplanted
with Gelfoam as a carrier in immunocompromised mice.
Similar transplants were carried out using human bone marrow
mesenchymal stem cells (hBMMSCs) as another source of stem
cells. As expected, hBMMSCs were not capable of regenerating
tissue up to 8 weeks (data not shown). However, KPCs and
SKPs from different donors consistently regenerated connective
tissue-like transplants (5 out of 5 mice), with a more rapidly
growing tumor-like mass using KPCs as compared to SKPs
(Figure 2A). The human origin of cellular components of the
transplants was confirmed by immunostaining with specific
antibodies for human mitochondria (Figure 2B). Histological
features of the transplants resembled early connective tissue
phenotype including presence of type I collagen fibrils,
however, the characteristic keloid–like thick collagen bundles
were not observed (Figures 2B and 2C). Next, to assess the in vivo
bone regenerative capability, KPCs were implanted subcuta-
neously with hydroxyapatite/tricalcium phosphate (HA/TCP)
as a carrier in immunocompromised mice for 8 weeks.
Histological analyses revealed calcified nodules in both KPCs
and SKPs generated transplants (Figure 2D).
To further confirm that the isolated KPCs and SKPs are truly
stem cells, we carried out a series of transplantation using limiting
cell density dilution. As shown in Table S4, KPCs exhibited
stronger capability for tumor xenograft formation at a minimal
density of 1610
5cells after transplantation for 8 weeks as
compared to their counterparts, SKPs. We next performed serial
transplantation with hydrogel as a carrier using 2610
6 KPCs
subcutaneously transplanted into immunocompromised mice. At 4
weeks post-primary transplantation, the transplants were harvested
and digested single cells were re-transplanted into immunocom-
promised mice for another 4 weeks. Our results indicated that
KPCs recovered from secondary transplants maintained the in vivo
ability to form connective-like tissues (Figure 2E). These results
were unique and particularly striking, as KPCs transplanted to a
heterologous environment were capable of proliferating and
differentiating into scar-like connective tissues expressing type I
collagen. However, we were not successful in replicating the
human keloid tumor using the current transplant model,
suggesting that KPCs are not the sole contributor to the exuberant
scar growth. Therefore, we hypothesize that, aside from KPCs, the
environmental niche where KPCs reside, is capable to drive stem
cell proliferation and differentiation, and therefore regulates the
tumor-like keloid growth.
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unique inflammatory niche of KPCs
To further explore the concept of niche regulated keloid
fibroproliferative growth we next attempted to define the distinct
‘‘pathological’’ niche of keloid by screening a panel of candidate
inflammatory cytokines utilizing fresh keloid tissues from different
donors. Using a focused human cytokine array we found that the
levels of several mediators, including growth-regulated IL-6,
oncogene alpha (GROa), IL-1b, MIP-1d, RANTES, stem cell
factor (SCF), TGF-b1, TNF-a, angiogenin II, vascular endothelial
growth factor (VEGF) and platelet-derived growth factor beta
homodimer (PDGF-BB), were increased by more than 2-folds in
keloid tissues as compared to matched normal skin tissues
(Figure 3A; Table S3). Particularly, an elevated level of IL-6, a
critical cytokine of the TH2 cells, and its receptor IL-6R, were
detected in all keloid tissues screened and further confirmed by
immunohistochemical studies (Figure 3C; Figure S4A) and Western
blot analysis (Figure 3F; Figure S4B). Both IL-6 and IL-6R were
expressed in SKPs and KPCs, with a relatively higher level in KPCs
as compared to the matched SKPs, as determined by Western blot,
RT-PCR and flow cytometry (Figures 3G and 3H; Figure S4C).
Another important inflammatory cytokine of the TH17 cells
[38–41], IL-17, was abundantly expressed in keloid tissues
as demonstrated by ELISA (Figure 3B) and further confirmed by
immunohistochemical staining (Figure 3C) and Western blot
analysis (Figure 3E). The increased expression of IL-17 in keloid
tissues was discernible around T-cell receptor CD3-positive
cells as determined by dual-color immunofluorescence staining
(Figure 3D). IL-17 has been reported to be produced almost
exclusively by activated T cells, but its receptor is widely expressed
in various cell types [42]. Herein, we observed an elevated
expression of IL-17R in KPCs as compared to SKPs (Figure 3I;
Figure S4C). However, the expression of IL-17 was undetectable
in both KPCs and SKPs (data not shown). Taken together, these
findings suggest that IL-6 and IL-17 are abundant components of
the unique inflammatory niche of keloid and may contribute to the
regulation of self-renewal and differentiation of keloid stem cells.
IL-17 is involved in the regulation of hTERT expression in
KPCs via coordinating IL-6 paracrine loop
IL-6 plays an important role in regulating self-renewal and
differentiation of stem cells [21,22,25], as well as tumor growth
[25–27]. Our data showed that IL-6 stimulated BrdU incorpora-
tion in both KPCs and SKPs (Figure 4A). Exposure of KPCs and
SKPs to exogenous IL-6 resulted in a dose-dependent increase in
Oct-4 expression at both mRNA and protein levels (Figures 4B
and 4C). In parallel studies, we found that incubation with IL-6
enhanced telomerase (hTERT) expression and enzyme activities in
both KPCs and SKPs (Figures 4D, 4E and 4F). The basal level of
hTERT was always higher in KPCs as compared to SKPs. Since
KPCs constitutively expressed a higher level of IL-6 and IL-6R
than SKPs (Figures 3G and 3H; Figure S4C), we next tested
whether the intrinsically secreted IL-6 might contribute to the
elevated telomerase expression and activity in KPCs. Our data
showed that treatment with IL-6 neutralizing antibodies sup-
pressed hTERT expression in both KPCs and SKPs (Figures 4G
and 4H) in a dose-dependent manner. However, IL-6 showed no
obvious effects on SSEA-4 expression in both SKPs and KPCs as
determined by flow cytometry (Figure S5A). Taken together, these
data suggest that IL-6 plays a critical role in the regulation of self-
renewal and proliferation of KPCs by regulating essential
functional genes such as hTERT and Oct-4.
Figure 2. In vivo transplantation of dermal stem cells. A, Size and volume of transplants generated from SKPs and KPCs using Gelfoam as a
carrier for 8 weeks (mean6SEM). ** P,0.01. B, Immunohistological studies of KPC transplant tissues using a specific antibody for human
mitochondria (purple color) and type I collagen (brown color), respectively. Scale bars, 50 mm. C, H & E histological stain of transplants. Scale bars,
50 mm. D, In vivo bone regeneration by SKPs or KPCs using hydroxyapatite/tricalcium phosphate (HA/TCP) as carrier. Scale bars, 50 mm. E, Serial
transplantation of KPCs. KPCs (2610
6) with hydrogel were injected subcutaneously into nude mice. After 4 weeks, the transplanted were harvested
and the recovered cells were expanded in vitro and re-transplanted into mice for another 4 weeks. The transplant tissues were harvested for H & E
staining or immunohistochemical (IHC) staining with a specific antibody for human mitochondria (purple color). Scale bars, 50 mm. The results are
representative of five independent experiments.
doi:10.1371/journal.pone.0007798.g002
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lineage commitment of pathogenic IL-17-producing T helper cells
(TH17 cells) from naı ¨ve T cells [67–69]. On the other hand, IL-17
induces the secretion of IL-6 in a variety of cells including
fibroblasts [44,50] and epithelial cells [51]. We then explored the
interaction between IL-6 and IL-17 and determine whether the
IL-17/IL-6 axis contributes to the regulation of the keloid niche.
Our results showed that incubation with IL-17 enhanced IL-6
expression in both SKPs and KPCs (Figure 5A). However,
exposure of KPCs to exogenous IL-6 failed to stimulate IL-17
secretion (data not shown). Similar to IL-6, IL-17 enhanced
hTERT and Oct-4 expression in both SKPs and KPCs (Figure 5B).
Treatment with IL-6 neutralizing antibody decreased the basal
level of hTERT and Oct-4, and in conjunction with IL-17
antibody only slightly augmented the blockade of hTERT and
Oct-4 expression in both SKPs and KPCs (Figure 5C). To further
delineate the relationship of IL-6 and IL-17 in the regulation of
hTERT and Oct-4 expression in SKPs and KPCs, we pretreated
cells with neutralizing antibody for either IL-17, or IL-6, or both
followed by IL-17 exposure. Our results indicated that IL-17-
induced hTERT and Oct-4 expression was abolished by
pretreatment with neutralizing antibody for either IL-17, or IL-
Figure 3. Increased expression of IL-6 and IL-17 in keloids. A, Cytokine expression profiling of keloid and matched normal skin tissue lysates
by human cytokine antibody array. B, Determination of IL-17 levels in keloid and normal skin tissue lysates by ELISA (mean6SEM). * P,0.05. C,
Immunohistochemical studies of IL-6 and IL-17 expression in keloid and matched normal skin tissues. Scale bars, 50 mm. D, Confocal
immunofluorescence studies show co-localization of IL-17 around CD3
+ cells as determined by dual-color staining. Scale bars, 100 mm. E and F,
Western analysis of IL-17 (E) and IL-6 expression (F) in keloid tissues and matched normal skins. G and H, Expression of IL-6 and IL-6 receptor (IL-6R) in
precursor cells derived from different keloid samples (K1, K2) and matched normal skins (N1, N2) as determined by Western blot (G) and RT-PCR
analyses (H). I, Expression of IL-17 receptor (IL-17R) in precursor cells derived from different keloid samples (K1, K2) and matched normal skins (N1, N2)
as determined by western blot and RT-PCR analyses. Data are representative of at least five independent experiments using KPCs and matched SKPs
from different patient donors (n=5).
doi:10.1371/journal.pone.0007798.g003
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hTERT and Oct-4 expression was only negated by pre-treatment
with IL-6 neutralizing antibody, not by IL-17 neutralizing
antibody (Figure 5E). Meanwhile, we examined whether treatment
with IL-6 and IL-17 neutralizing antibodies had any effects on cell
proliferation and cell viability of SKPs and KPCs. Our results
showed that treatment with IL-6, but not IL-17, neutralizing
antibodies moderately inhibited BrdU incorporation (P,0.05)
(Figure S5C), but had no obvious effects on cell viability (Figure
S5B). We observed no apparent morphologic change character-
istic of apoptosis after treatment with IL-6 and/or IL-17
neutralizing antibodies (data not shown). In all experiments, an
isotype-matched antibody (mouse IgG) was used as negative
controls. Taken together, these results suggest that IL-17 induces
hTERT and Oct-4 expression in SKPs and KPCs by orchestrating
the downstream IL-6 paracrine loop.
IL-17/IL-6 axis contributes to the fibroproliferative
growth of KPCs-generated transplants
In order to recapitulate the distinct ‘‘pathological’’ niche of
keloid, we engineered the in vitro inflammatory niche by
incorporating IL-6 non-covalently into the hydrogel carrier. KPCs
and SKPs (2610
6) were mixed with IL-6-linked carrier and
immediately injected subcutaneously on the dorsal surface of
immunocompromised mice. Our results showed that KPCs-
generated transplant grew faster than that from SKPs, and the
Figure 4. IL-6 increases Oct-4 and telomerase expression in KPCs and SKPs. A, KPCs and SKPs were cultured in 1% FBS for 24 hours
followed by exposure to different concentrations of IL-6, and BrdU incorporation in KPCs and SKPs was determined (mean6SEM). ** P,0.01. B,
Expression of Oct-4 mRNA and protein were determined by Western blotting (WB) and RT-PCR, respectively. C, Immunofluorescence studies of Oct-4
expression in SKP and KPC after incubated with 20 ng/ml IL-6 for 24 hours. Scale bars, 20 mm. D, Expression of hTERT mRNA and protein were
determined by Western blotting (WB) and RT-PCR, respectively. E, Immunofluorescence studies of hTERT expression in SKP and KPC following
incubation with 20 ng/ml IL-6 for 24 hours. Scale bars, 20 mm. F, Telomerase enzyme activity of SKPs and KPCs in response to IL-6 as determined by
TeloTAGGG Telomerase PCR ELISA. G and H, Treatment with neutralizing antibody for IL-6 (IL-6Ab) decreased the basal level of hTERT as determined
by Western blotting (G) and TeloTAGGG Telomerase PCR ELISA (H). An isotype-matched normal mice IgG (mIgG) was used as negative control
(mean6SEM). * P,0.05; ** P,0.01; *** P,0.001; ns, no significance. The results are representative of at least five independent experiments using
KPCs and the matched SKPs from different patient donors (n=5).
doi:10.1371/journal.pone.0007798.g004
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vivo growth of both KPCs and SKPs (Figure 6A). Histological
analyses revealed significant increase in cellular components and
type I collagen expression in all transplants using IL-6-retained
hydrogel as compared to hydrogel only (Figures 6B and 6C). The
collagen structure of IL-6 treated transplant was more fibrillar and
less amorphous. Importantly, abundant keloid-like thick collagen
fibrils were observed in KPC transplants treated with IL-6 as
demonstrated by histological and immunohistological staining
(Figures 6B and 6C), and electron microscopy (Figure 6D). The
unique pattern of excessive intracellular and extracellular
accumulation of collagen seen in KPC transplants resembled the
abundant collagen matrix observed in keloid tissues (Figure S1B).
Meanwhile, we demonstrated that transplants generated from
KPCs and SKPs in the presence of IL-6 expressed higher levels of
Oct-4 and hTERT, as well as an elevated hTERT enzyme
activity, as compared to control (Figures 6E, 6F and 6G). The
increased proliferation of dermal stem cells by IL-6 was further
confirmed by immunohistochemical staining with antibody for
human PCNA (proliferating cell nuclear antigen) (Figure 6H).
These results provide further evidence that IL-6, as a downstream
target of IL-17 and an essential component of the unique
Figure 5. IL-17-induced hTERT and Oct-4 expression is IL-6-dependent. A, IL-17 stimulated IL-6 secretion in SKPs and KPCs as determined by
ELISA analysis (mean6SEM). ** P,0.01; ns, no significance. B, IL-17 stimulated the expression of hTERT and Oct-4 in SKPs and KPCs as determined by
Western blot analysis. C, Blocking IL-6, but not IL-17 attenuated the basal expression of hTERT and Oct-4 in SKPs and KPCs. Cells were treated with
5 mg/mL of neutralizing antibody for either IL-6 (IL-6 Ab), or IL-17 (IL-17Ab), or both for 24 hours and expression of hTERT and Oct-4 was determined
by Western blot analysis. D, IL-17-induced upregulation of hTERT and Oct-4 expression in SKPs and KPCs was significantly attenuated by treatment
with neutralizing antibodies for either IL-17, or IL-6, or both. After serum-starved for 24 hours, cells were pretreated with neutralizing antibodies,
followed by incubation with 20 ng/mL of IL-17. The expression of hTERT and Oct-4 was determined by Western blot analysis. E, IL-6-induced
upregulation of hTERT and Oct-4 expression in SKPs and KPCs was attenuated only by IL-6Ab, not by IL-17Ab. Following serum-starvation for
24 hours, cells were pretreated with neutralizing antibodies and incubated with 20 ng/mL of IL-6. Expression of hTERT and Oct-4 was determined by
Western blot analysis. An isotype-matched normal mouse IgG (mIgG) was used as negative controls. The results are representative of at least five
independent experiments using KPCs and the matched SKPs from different patient donors (n=5).
doi:10.1371/journal.pone.0007798.g005
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of self-renewal and differentiation of keloid stem cells.
To explore whether IL-6 played a role in the initiation of KPC-
generated transplants, KPCs mixed with hydrogel with or without
human IL-6 neutralizing antibody were injected subcutaneously
into immunocompromised mice whereas isotype-matched anti-
body (mouse IgG) was used as negative control. Our results
indicated that treatment with IL-6 neutralizing antibody signifi-
cantly suppressed the in vivo growth of KPC-generated transplants
(Figure 6I). We next examined whether IL-6 was capable of
maintaining the growth of KPC-generated transplants. KPCs
mixed with hydrogel were injected subcutaneously into immuno-
Figure 6. In vivo effect of IL-6-linked hydrogel on growth of transplanted KPCs and SKPs. A, KPCs or SKPs (2610
6) were mixed with
hydrogel incorporated with or without IL-6 and subcutaneously injected into immunocompromised mice for 8 weeks. Size and volume of transplants
generated from KPCs and SKPs were measured (mean6SEM). Scale bars, 1 mm. ** P,0.01; *** P,0.001. B, Histological analysis of KPC and SKP
transplants by hematoxylin and eosin (H & E) staining. Scale bars, 50 mm. C, Immunohistochemical studies (IHC) of transplants of KPCs and SKPs using
antibody specific for human mitochondria (purple color) and type I collagen (brown color) or an isotype-matched control IgG (IgG isotype), and then
counterstained with hematoxylin (nuclei, blue). Scale bars, 50 mm. D, Increased synthesis and secretion of collagen by IL-6 in KPCs versus SKPs
generated transplants as demonstrated by electron microscopy (EM). N, nucleus; C, cytoplasm; IC, intracellular collagen; EC, extracellular collagen.
Scale bars, 500 nm. E, Expression of Oct-4 and hTERT in KPC and SKP transplants with or without IL-6 as determined by Western blot analysis. F,
Expression of Oct-4 and hTERT in KPC and SKP transplants with or without IL-6 as determined by immunohistochemical studies. Scale bars, 50 mm. G,
Telomerase enzyme activity of SKPs and KPCs transplants with or without IL-6 as determined by TeloTAGGG Telomerase PCR ELISA (mean6SEM).
* P,0.05; ** P,0.01. H, Increased expression of proliferating cell nuclear antigen (PCNA) in transplants of SKPs and KPCs in the presence of IL-6 as
determined by immunohistochemical studies. Scale bars, 50 mm. I and J, Treatment with neutralizing antibodies against IL-6 inhibited in vivo
formation and growth maintenance of KPC transplants. KPCs were mixed with hydrogel with or without IL-6 neutralizing antibody (IL-6Ab, 10 mg/ml)
and injected subcutaneously into immunocompromised mice. KPC transplants were evaluated after 8 weeks (I). To test the inhibitory effect of IL-6
neutralizing antibody on growth of KPC-derived transplant, IL-6 neutralizing antibody was locally injected into KPC-transplants twice a week (5 mg/
time) for another 4 weeks (J). An isotype-matched normal mice IgG (IgG isotype) was used as negative controls. The results are representative of five
independent experiments using KPCs and the matched SKPs from different patient donors (mean6SEM). ** P,0.01; ns, no significance.
doi:10.1371/journal.pone.0007798.g006
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was injected locally into the transplant, twice a week (5 mg/
injection) for 4 weeks. Our results showed that intra-lesional
injection with IL-6 neutralizing antibody significantly reduced the
size of KPC-generated transplants (Figure 6J). These results
provide further evidence that IL-6 plays an important role in both
initiation and maintenance of KPC transplants, suggesting a
potential anti-scarring therapeutic effect.
Since our KPC transplant studies were carried out in athymic
nude (nu/nu) mouse which might be devoid of functional T
lymphocytes [70], we transplanted KPCs using hydrogel with and
without IL-6 into immunocompromised mice adapted by
CD4
+CD25- T-lymphocytes (Naı ¨ve T) infusion. Our results
showed that boosting T cell function in immunocompromised
mice significantly promoted growth of KPC transplants, in the
presence or absence of IL-6 (Figure 7A). Immunofluorescence
studies showed an increased expression of IL-17 by CD4 positive-
T-lymphocytes, which was further enhanced by IL-6 treatment
(Figure 7B). The increased IL-17 expression was further confirmed
by ELISA assay (Figure 7C). All together, our results suggest that
the IL-17/IL-6 axis may function to maintain the highly elevated
IL-6 level in the distinct keloid niche with abilities to regulate key
stem cell functions such as hTERT and Oct-4 expression, thus
contributing to the formation of the benign keloid growth.
Discussion
Unlike a more precise topographical organization of epithelial
stem cells in skin epithelium, the dermal layer harbors Oct-4 and
SSEA-4 positive cells that are randomly distributed in the reticular
dermis, interspersed among thick ECM, as seen abundantly
resided in keloid tissues. The relatively abundant expression of two
major markers for embryonic and mesenchymal stem cells
[54,64,65], Oct-4 and SSEA-4, in keloid as compared to normal
skin tissues, suggests the presence of postnatal stem cells in
pathologic scar and may contribute to its persistent growth.
In the last few decades, several groups have shown that
multipotent precursor cells can be generated from different
normal adult human tissues [64–66,71,72], and may share
common biological properties, including the expression profile of
various cell surface markers and embryonic transcription
m a r k e r sa sw e l la st h e i rm u l t i p o t e n t differentiation capabilities
[10,66,71]. Thus, adult stem cells may play an essential role in
growth, homeostasis and regeneration of many tissues. However,
up to date, how stem cells contribute to pathologic diseases
remains largelyunknown.Recently, several studies have reported
the isolation and characterization of precursor cells from normal
rodent and human normal skin dermis (SKPs) [54–56], and
recently, mesenchymal-like stem cells from keloid scars
(KMLSCs) [73]. However, to our knowledge, no study has
determined whether SKPs differ from precursor cells derived
from their aberrant scars, specifically their in vivo self-renewal and
regenerative capacities, and more importantly, whether the
pathological niche driven by the inflammatory cytokines of the
keloid scar affect their growth and differentiation. In this study,
we have isolated and characterized a population of keloid derived
precursor cells, termed KPCs, which share some stem cell
properties as KMLSCs [73], including self-renewal, clonogene-
city and multiple differentiation capacities. However, KPCs
inherently expressed higher levels of pluripotent-specific tran-
scription factors Oct-4 and telomerase activity, increased
clonogenicity and proliferative capabilities as compared to SKPs
derived from the same donor. Based on these distinct stem cell
properties, KPCs may represent the benign tumor-like stem cell
counterpart of SKPs which might contribute, at least in part, to
the high proliferative state in keloid tumor.
Figure 7. Effect of T cell infusion on in vivo growth of KPC-generated transplants. A, Size and volume of KPC transplants (mean6SEM).
Activated CD4
+CD25
2 T lymphocytes were infused at 1610
6/mouse through the tail vein two days before KPC transplants. KPCs were mixed with
hydrogel with or without IL-6 and transplanted subcutaneously for 8 weeks. * P,0.05; ** P,0.01. B, Dual-color immunostaining for mouse CD4 (red)
and IL-17 (green) using paraffin-embedded sections of KPC transplants. Scale bars, 50 mm. (C) Tissue lysates were prepared from the transplant
tissues, and IL-17 expression was analyzed by ELISA (mean6SEM). * P,0.05, ** P,0.01. The results are representative of five independent
experiments using KPCs and the matched SKPs from different patient donors.
doi:10.1371/journal.pone.0007798.g007
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critical role of stem cell niche in the regulation of stem cell
functions. The balance between proliferation-inhibiting and
proliferation-promoting signals provided by the specialized niche
microenvironment is the key to homeostatic regulation of stem cell
maintenance versus tissue regeneration [12]. Therefore, any
changes in the niche components will lead to alterations of stem
cell functions. A decline in signaling from the niche that is essential
to the maintenance of stem cells can lead to aging and even loss of
stem cell number and function [74,75], thus contributing to aging
or degenerative diseases. On the other hand, deregulation or
alteration of the niche by dominant proliferation-promoting
signals may lead to overgrowth of resident stem cells, thus
contributing to hyper-proliferative diseases, benign and malignant
tumors [12]. Keloid, a fibro-proliferative benign tumor of skin, is
characterized by chronic inflammation, an increased infiltration of
inflammatory cells, an enriched milieu of cytokines and growth
factors, and an abundant accumulation of ECM [1,2,57], thus
providing a unique inflammatory niche for the resident stem cells.
Using keloid as a niche-related disease model we explore the
critical niche components and their role in the regulation of stem
cell functions.
IL-6, an inflammatory cytokine, plays a critical role in the
pathogenesis of most fibrotic diseases [18] and chronic inflamma-
tion-associated tumorigenesis [23,24]. Consistent with previous
reports [5,6], we have demonstrated that IL-6 is significantly up-
regulated in keloid scars versus their normal skin counterparts, and
KPCs constitutively express a higher level of IL-6 and IL-6R
compared to SKPs. Moreover, our results show that IL-6 can
significantly stimulate the expression of both Oct-4 and telome-
rase, two important stem cell function genes, in cultured KPCs
and SKPs, and incubation with specific IL-6 neutralizing
antibodies suppressed the constitutive expression of telomerase in
KPCs. These findings support our hypothesis that the locally
enriched IL-6 in keloid scars might constitute a major component
of the inflammatory niche where KPCs reside and play a critical
role in the regulation of KPC functions.
Since an animal model for keloid scar does not currently exist,
we proposed to generate keloid tumor using dermal derived
precursor cells. To recapitulate the ‘‘pathological’’ niche of keloid,
we utilized a newly introduced carrier Extracel-HP
TM Hydrogel
conjugated with IL-6 for the in vivo transplantation of KPCs
[61,62]. We have demonstrated that IL-6 stimulates the expression
of Oct-4 and telomerase in vivo and significantly promotes the
growth of KPCs and SKPs-generated transplants. More impor-
tantly, abundant keloid-like collagen fibrils were accumulated in
transplants of KPCs in the presence of IL-6 that resembled the
characteristic histological features of keloid scars. Using the
current KPCs-generated transplant as a keloid model we
attempted to treat with IL-6 neutralizing antibody using standard
intra-lesional injection approach and showed significant reduction
in keloid size. Furthermore, pre-treatment of KPCs with IL-6
neutralizing antibody significantly suppressed the in vivo growth of
KPCs-generated transplant, suggesting a potential anti-scarring
preventive and therapeutic effect. Taken together, these important
findings further support the notion that IL-6, as a major
component of the inflammatory niche in keloid scars, may play
a critical role in the acquirement of benign tumor-like stem cell
phenotypes, therefore the benign tumor growth.
IL-17, another recently identified inflammatory cytokine,
exclusively produced by activated T cells and whose receptor is
widely expressed in many cell types [42], plays a pivotal role in
several inflammatory diseases [38–41]. IL-6, in concert with TGF-
b, induces TH17 cell differentiation from naı ¨ve T cells by
orchestrating a series of ‘‘downstream’’ cytokine-dependent
signaling pathways [67–69]. More importantly, IL-6 has been
reported to function both upstream and downstream of IL-17,
constituting a positive feedback loop that promotes autoimmune
and allergic diseases [50,51]. In this study, we have demonstrated
for the first time to our knowledge that IL-17 is up-regulated in
keloid tissues, and KPCs express relatively higher IL-17R than
normal skin-derived precursor cells. Furthermore, we demonstrat-
ed that blocking IL-6 abolished IL-17-induced up-regulation of
hTERT and Oct-4 expression; however, blocking IL-17 failed to
attenuate IL-6-induced up-regulation of hTERT and Oct-4
expression in KPCs. These findings support our hypothesis that
elevated IL-6 and TGF-b in keloids promote differentiation of
TH17 cells, which in turn secretes more IL-17 to further enhance
the release of IL-6 from keloid stem cells or other stromal cells.
The IL-17-triggered positive-feedback loop via paracrine IL-6
induction constitutes the ‘‘pathological’’ niche or altered inflam-
matory niche that drives KPCs toward proliferation, and thus
tumor-like keloid growth (Figure S6). However, it is important to
emphasize that despite the tumor-like growth behavior, KPCs
were distinct from cancer cells or cancer stem-like cells (25) in that
KPCs displayed a normal karyotype and an absence of cytogenetic
abnormalities. Since inflammation plays a critical role in
tumorigenesis (23, 24), longer in vivo experimental observation,
up to 2 months in our study, was carried out to determine the
long-term effects of inflammatory niche components, specifically
the IL-17/IL-6 axis, on the acquired properties of KPCs,
including their replicative/proliferative capabilities, and cellular
transformation. Due to the limitation of the biological activity of
the hydrogel-released growth factors, we were not able to prolong
the study beyond the above time point. Further studies will be
needed to determine the effect of chronic inflammation on
potential tumorigenesis.
In addition to providing proliferation and differentiation signals,
stem cell niche also provides homing signals to recruit bone
marrow MSCs to sites of injury and inflammation [10,12],
whereby a variety of inflammatory mediators, including hypoxia,
reactive oxygen species (ROS), inflammatory chemokines and
cytokines, may trigger the migration of BMMSCs [76]. In
response to the unique tumor microenvironment of chronic
inflammation [77,78], BMMSCs may acquire the cancer-associ-
ated fibroblast (CAF) phenotype and subsequently promote tumor
growth and metastasis via the production of pro-angiogenic and
tumor stimulating paracrine factors [79,80]. Using a dual-
chamber cell-migration assay, keloid-derived fibroblasts have been
shown to induce human BMMSCs chemoattraction toward keloid
cells, and develop myofibroblastic changes characterized by
abundant rough endoplasmic reticulum, secretion of collagen-like
fibers as well as actin-type microfilament bundles [7]. These
findings suggest that the unique keloid microenvironment or niche
may preferentially recruit bone marrow MSCs and sustain their
interaction with resident fibroblasts, thus contributing to keloid
formation by producing abundant extracellular matrix at the scar
site. The interaction between the keloid niche and keloid derived
stem cells, KPCs, has been demonstrated here in our study, which
is sustained by the IL-17/IL-6 feedback loop. It remains to be
determined whether IL-17/IL-6 axis contributes to the recruit-
ment of BMMSCs to keloid lesion and whether KPCs represent a
distinct population of resident MSCs or derived from BMMSCs.
In addition, a recent study reported that methylprednisolone is
capable of inhibiting IL-17 production in lymphocytes and lymph
node cells [81]. Further studies are needed to determine whether
the anti-scarring effect of the intralesional steroid therapy in keloid
scar correlates with its role on the regulation of the IL-17/IL-6.
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further investigate the interplay between stem cells and their
immediate niche.
In summary, we have successfully identified multipotent
precursor cells from keloid scars and provided evidence supporting
IL-17/IL-6 axis as an essential component of the unique keloid
niche that provides extra proliferation-promoting signals to
resident stem cells. Based on our findings, we postulate that the
inflammatory stimuli, i.e., inflammatory infiltrates and enriched
cytokines, induced by wounding, surgical injury, or infection, may
produce a persistent state of chronic inflammation at the wound
site. The increased IL-6, a major component of the inflammatory
niche, in conjunction with TGFb1, may trigger the differentiation
of naı ¨ve T cells into TH17 cells, which further stimulate IL-6
secretion via IL-17, thus creating an enriched pro-inflammatory
cytokine milieu. The functionally altered niche can promote the
resident stem cells to acquire a benign tumor-like stem cell
phenotype characterized by increased cell proliferation and
differentiation, therefore directly drives the benign tumor growth
as seen in keloids (Figure S6). Findings from this study have not
only substantiated our current knowledge regarding the potential
role of adult stem cells in pathologic diseases, specifically skin
fibrosis, and other fibro-proliferative disorders, but most impor-
tantly, have provided a promising niche-related disease model, to
further explore the intricate interactions between stem cells and
their functional niche components, and ultimately lead to the
development of an animal model for keloid fibrosis. Finally, this
study should open a new avenue for stem cell research on benign
tumor and lead to the rational design and development of
innovative methods for prevention and treatment of niche-related
diseases by specifically modulating or targeting the unique niche
microenvironment of adult stem cells.
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Table S1 Antibodies for immunostaining and neutralization
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Figure S1 Isolation of precursor cells from keloid tissues. (A)
Keloid scar displays benign tumor phenotype in terms of growth
and recurrence. (B) H&E histological stain of keloid tissues and the
matched peripheral normal skins. PD: papillary dermis; RD:
reticular dermis. Scale bars, 50 mm. (C) Semi-quantification of
immunohistochemical staining of Oct-4 and SSEA-4 in keloid and
the matched normal skin (Fig. 1A) as described in Materials &
Methods. **P,0.01. (D) Colony formation of stem cells derived
from keloid (KPCs) and normal skin (SKPs). (E) Subcloning and
culture of mesenchymal stem cells from keloids (KPCs) in a-MEM
medium supplemented with 10% FBS, 1 x NEAA (non-essential
amino acid) and antibiotics. Scale bars, 100 mm. (F) Determination
of doubling time of KPCs and SKPs as described in Materials and
Methods (mean6SEM). (G) Karyotyping of the SKP and KPC
clones at passage 10. The results are representative of at least five
independent experiments.
Found at: doi:10.1371/journal.pone.0007798.s006 (7.14 MB TIF)
Figure S2 Multipotent differentiation of keloid derived precur-
sor cells (KPCs). (A–C) Adipogenic differentiation of SKP or KPC
as determined by Oil Red O staining (A and B) and RT-PCR
analysis of specific adipocyte genes (C). (D–F) Osteogenic
differentiation as determined by Alizarin Red S staining (D and
E) and RT-PCR analysis of osteocalcin gene (F). Human bone
marrow mesenchymal stem cells (hBMMSCs) were used as
positive controls whereas KPCs culturing under normal growth
medium were served as non-induction control. Scale bars, 50 mm.
Data are representative of at least five independent experiments
using KPCs and the matched SKPs from 5 different patient donors
(mean6SEM). * P,0.05; ns, no significance.
Found at: doi:10.1371/journal.pone.0007798.s007 (5.20 MB TIF)
Figure S3 Sphere-colony formation of KPCs. (A) Subcloning
and expansion of sphere-colonies derived from keloids in DMEM-
LG/F12 (3:1) supplemented with 40 ng/mL FGF-2, 20 ng/mL
EGF, B27 and antibiotics. Scale bars, 100 mm. (B and C)
Expression of stem cell markers and BrdU incorporation by
keloid-derived sphere colonies (K1,K3) as determined by
immunofluorescence staining (B) and RT-PCR analysis (C). Scale
bars, 50 mm. (D) Multipotent differentiation of keloid-derived
sphere colonies into different lineages of neural cells, adipocytes,
and osteocytes as determined by immunofluorescence staining
with specific neural cell markers, Oil Red O and von Kossa
staining. Scale bars, 50 mm. The results are representative of at
lease five independent experiments.
Found at: doi:10.1371/journal.pone.0007798.s008 (4.37 MB TIF)
Figure S4 Expression of IL-6 receptor (IL-6R) in keloids (K1,
K2) and matched normal skins (N1, N2). (A) Paraffin-embedded
sections of keloid and the matched normal skin were immuno-
stained with a specific antibody for human IL-6R or an isotype-
matched control IgG. Scale bars, 50 mm. (B) Western blot analysis
of IL-6R in tissue lysates. (C) Flow cytometric analysis of IL-6R
and IL-17R expression in cultured SKPs or KPCs. The results are
representative of five independent experiments.
Found at: doi:10.1371/journal.pone.0007798.s009 (1.72 MB TIF)
Figure S5 Effect of IL-6 on the expression of SSEA-4 and BrdU
incorporation in SKPs and KPCs. (A) Cells were stimulated with
20 ng/ml IL-6 for 24 h followed by immunostained with
antibodies for SSEA-4 and FITC-conjugated secondary antibody
and analyzed by flow cytometry. (B and C) Effects of IL-6 and IL-
17 neutralizing antibodies on cell viability and proliferation in
SKPs and KPCs. Cells were treated for 24 h with 5 mg/ml of
neutralizing antibodies for human IL-6, or IL-17, or both in the
absence of IL-6 and IL-17, whereby an isotype-matched normal
mice antibody (mIgG) was used as negative controls. Cell viability
and proliferation were determined by MTT (B) and BrdU
incorporation assay (C), respectively. The results are representative
of at least five independent experiments (mean6SEM). #,n o
significant difference; * P,0.05, as compared with non-treatment
control.
Found at: doi:10.1371/journal.pone.0007798.s010 (0.45 MB
DOC)
Figure S6 Schemed inflammatory niche-driven benign tumor
growth model. Under the chronic inflammatory microenviron-
ment, keloid-derived precursor cells (KPCs) are persistently
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milieu of pro-inflammatory mediators, specifically IL-6, and then
acquired a benign tumor-like stem cell phenotype characterized by
moderately increased telomerase activity, and consequently, an
increased proliferative capacity, whereby the increased IL-17
continuously drives this process by augmenting the production of
IL-6 by KPCs, thus leading to the overgrowth of keloid benign
tumor.
Found at: doi:10.1371/journal.pone.0007798.s011 (0.87 MB
DOC)
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